Please use this identifier to cite or link to this item:
DC FieldValueLanguage
dc.contributor.authorMugabo, P-
dc.contributor.authorHassan, Mogamat Shafick-
dc.contributor.authorSlaughter, R-
dc.description.abstractThe aim of this study was to compare the pharmacokinetics of antituberculosis drugs in patients with pulmonary tuberculosis (PTB) and in patients with PTB and HIV during the first 24 h of treatment. Methods: Designed a case-control study, it compares the pharmacokinetics of first line antituberculous drugs, in HIV-positive (cases) and HIV-negative (control) patients both presenting with pulmonary tuberculosis. Blood samples were collected before and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 8, 12 and 24 h after administration of drugs. Drugs plasma levels were tested using HPLC assays. Results: Fourteen HIV positive (7 males and 7 females) and 17 HIV negative (9 males and 8 females) enrolled. Rifafour, a combination tablet including rifampicin, isoniazid, pyrazinamide and ethambutol was used in HIV positive patients, CD4 counts were significantly lower, renal function mildly decreased in 85% patients and moderately decreased in 7% patients. Liver function was normal in both groups. None of these patients was on other drug therapy. In the HIV positive group isoniazid T1/2 and AUC were decreased and Cl increased whereas Tmax and Cmax were unchanged. Pyrazinamide Tmax and Cmax were significantly decreased in HIV positive patients and no significant changes were noticed in the T1/2, AUC and CL. Conclusion: The study suggest that ethambutol,en_US
dc.description.sponsorshipUniversity of the Western Cape and Cape Peninsula University of Technologyen_US
dc.publisherDavid publishingen_US
dc.subjectHIV infectionen_US
dc.titleAcute pharmacokinetics of first line anti- tuberculosis drugs in patients with pulmonary tuberculosis and in patients with pulmonary tuberculosis co-infected with HIVen_US
Appears in Collections:HWSci - Journal Articles (not DHET subsidised)
Files in This Item:
File Description SizeFormat 
Mugabo_P_Hassan_MS_Slaughter_R _Acute Pharmacokinetics of First Line Anti-tuberculosis_pdfMain article113.26 kBAdobe PDFView/Open
Show simple item record

Page view(s)

Last Week
Last month
checked on Feb 9, 2021


checked on Feb 9, 2021

Google ScholarTM


This item is licensed under a Creative Commons License Creative Commons